Why is GTBP stock up today?

In plain English

The only news (“A Third Cancer Drug Just Entered the Clinic at an Under-$2…”) is stale (101d old) — too old to explain today's move. Likely momentum, not news.

What it means for you

Finished the day strong — closed near its highs on heavy volume. Risk level: moderate.

About GT Biopharma Inc. Common Stock

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers i

See it in context

GTBP opened +6.6% versus the prior close, then finished +30.7% from its open, on 0.5M shares traded.

Against the whole market that day, 64.5% of US stocks closed higher (median move +0.4%) — so GTBP was moving with a broadly higher market. See the full market recap →

More movers: today's biggest gainers · today's biggest gap-ups · all screeners · why other stocks are moving

Learn the basics: how to read a chart · what volume means · grade GTBP’s chart with the AI reader →